Experimental analysis reveals that CD44 targeting reduces immunosuppressive bone marrow derived cells in pancreatic cancer, suggesting a novel therapeutic strategy.
Pancreatic ductal adenocarcinoma (PDAC) is characterized by early dissemination and an aggressive metastatic course. In order to establish in the liver, metastatic cells require a metastatic niche providing prosurvival signals. Here, we demonstrate that bone marrow derived cells (BMDCs) establish immunosuppressive niches in the liver that promote metastatic colonization in PDAC. Using an immunocompetent orthotopic PDAC mouse model, we show that BMDCs form clusters enriched in myeloid progenitors and display upregulation of migratory, adhesive, and immunoregulatory programs in response to tumor derived cues. CD44 and its splice variant CD44v6 are found to be highly expressed on these cells. Hematopoietic specific deletion of Cd44 or Cd44v6 using Cd44/Cd44v6fl/fl;VavCreERT2 mice markedly impairs BMDC clustering, reshapes the BMDC transcriptome, disrupting pathways critical for migration, adhesion, and immunosuppression thereby reducing metastatic burden. Mechanistically, CD44 inhibition blocks BMDC migration toward CCL2, CCL5, and CXCL12, and impairs adhesion to VCAM-1 and fibronectin. Functionally, Cd44 deficient BMDCs exhibit reduced expression of immunosuppressive mediators such as Arginase 1, Ido1, and Il10, and fail to suppress T cell proliferation. Our findings position CD44 as a pleiotropic regulator of BMDC mediated metastatic niche formation and identify it as a promising therapeutic target to disrupt the prometastatic microenvironment in PDAC.
No takes yet. Share an insight, caveat, or question.
Mehner et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: